IP Library Granted Patent US 11,613,517
Granted Patent B2
US 11,613,517 · App. 16/971,171 · Granted Mar 28, 2023

Amide prodrugs of small molecule nuclear receptor modulators

Inventors: Thomas S. Scanlan (Portland, OR); Skylar J. Ferrara (Portland, OR)
Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
C07C235/34C07C233/65C07C309/66C07D261/20C07D277/26C07D409/06C07C2602/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,613,517
App. No.
16/971,171
Granted
Mar 28, 2023
Kind
B2
Abstract

Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

Claims (4)

1. A compound:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

3. A method of treating a neurodegenerative disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: SCANLAN, THOMAS S.; FERRARA, SKYLAR J.
To: OREGON HEALTH & SCIENCE UNIVERSITY
Reel/Frame 053842/0767 →
Continuity (2)
Provisional Application 62637884 · Mar 2, 2018
Related Publication 20210087137A1 · Mar 25, 2021
Cited By (4)
US 12,466,781 US 12,528,761 US 12,590,072 US 12,637,413